Exanatide alternative to starting insulin in type 2 diabetes

For type 2 diabetes patients not controlled with oral hypoglycaemic drugs, exanatide may be an alternative to starting insulin treatment, three year findings from the DURATION-3 trial suggest.

A weekly injection of the long-acting GLP-1 receptor agonist provided better HbA1c control and also avoided weight gain and hypoglycaemic episodes seen with glargine insulin, according to study published in the Lancet Diabetes and Endocrinology.

However, exanatide was less well tolerated than insulin, the study showed.

In the